When Sun Pharma to lower prices for certain medicines and expand its American manufacturing commitments, it did more than secure relief from a potentially punishing tariff regime. It may have offered Indian drugmakers a glimpse of what doing business in the world’s largest pharmaceutical market could increasingly look like.
The bargain is significant: access and protection in exchange for lower prices, greater transparency and a deeper manufacturing footprint in the US.
For Indian pharmaceutical companies, which have built a formidable business by manufacturing medicines efficiently in India and exporting them across the world, that could mark a structural shift.
The question is no longer simply whether Indian companies can sell more medicines in the US: it is whether they may increasingly have to make more of them there too.
Namit Joshi, chairman of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), sees the Sun Pharma-US government agreement as potentially beneficial for both sides.
“I see the Sun-US govt deal as a win-win for both,” he says, adding that more companies could explore a similar route. Such agreements, he argues, can reduce uncertainty and ease pressure on companies’ profitability.
But there is an equally important caveat: India cannot allow its pharmaceutical export strategy to become excessively dependent on one market. Indian companies, Joshi says, also need to continue expanding elsewhere.
That balancing act may define the next phase of India’s pharmaceutical export story.
Sun Pharma is among nine additional pharmaceutical companies that signed agreements with the Trump administration under its Most-Favoured-Nation, or MFN, drug-pricing push.
The White House says these deals are aimed at bringing US drug prices closer to the lowest prices paid in other developed countries, while also encouraging companies to invest in American manufacturing and strengthen domestic drug supply chains.
For Sun Pharma, the agreement provides tariff relief in exchange for commitments linked to drug pricing and the broader US pharmaceutical supply chain. Under the administration’s policy, companies that enter MFN pricing agreements and meet approved onshoring commitments can receive preferential tariff treatment, including a temporary zero-tariff rate under specified conditions.
The logic behind the deal is therefore straightforward but consequential: the US government offers regulatory and tariff certainty, while pharmaceutical companies agree to help lower medicine prices and increase their strategic presence inside the US.
That could become an increasingly attractive proposition for Indian companies with large American businesses.
“I see the Sun Pharma deal as a template, but I don’t think it will be replicated uniformly,” pharma analyst Salil Kallianpur told India Today.
The companies most likely to consider such a model, he says, would be those “for whom the US is strategically indispensable and where higher-value portfolios can absorb the cost of localisation.”
This point is important because for a company selling large volumes of low-margin generic medicines, building and maintaining expensive US manufacturing infrastructure may make little financial sense.
But companies with speciality medicines, complex generics, injectables and differentiated products may be better placed to trade higher costs for greater pricing power, regulatory certainty and political goodwill.
According to Shrikant Akolkar, veteran pharma analyst with Nuvama Institutional Equities, only Sun among Indian companies seem to be fitting the bill for how the US administration wants to operate with pharma companies from abroad currently, but Kallianpur identifies Dr Reddy’s, Aurobindo, Lupin and Zydus as companies worth watching, although the rationale differs for each.
To understand why such a deal matters, it is important to understand an unusual feature of the US healthcare market: the manufacturer is only one part of the drug-pricing chain.
Healthcare in the US is largely insurance-driven. Unlike India, where health insurance has traditionally focused largely on hospitalisation, American insurance coverage also extends to prescription medicines for a substantial share of the population.
The drug, however, moves through a complex commercial ecosystem.
Large distributors procure medicines from manufacturers and supply them through the healthcare and pharmacy network. Pharmacy Benefit Managers, or PBMs, negotiate prices and rebates between drug manufacturers, insurers and pharmacies. Companies such as CVS Health’s pharmacy benefit business, Cigna and OptumRx are among the major players in this ecosystem.
The stated objective is to use purchasing power to obtain lower prices. But critics argue that the system has become opaque and that the financial incentives of intermediaries can distort what patients ultimately pay.
This system, says the Trump administration repeatedly, should be disrupted.
And the MFN pricing push is a step in that direction – seeking to address one of the biggest political paradoxes in American healthcare: medicines that are often sold more cheaply in other wealthy countries can cost significantly more in the US.
At the same time, the administration is pursuing another objective – reducing the US’ dependence on overseas pharmaceutical manufacturing. The April 2026 proclamation on pharmaceutical imports explicitly links drug affordability with supply-chain security and the expansion of domestic manufacturing.
In other words, Washington’s emerging formula appears to be: lower prices for Americans, more manufacturing in America and less strategic dependence on foreign supply chains.
For India, however, localisation in America presents both an opportunity and a risk.
Indian drugmakers have become globally competitive precisely because of India’s manufacturing ecosystem – its skilled workforce, scale, established plants and relatively lower production costs. If companies increasingly need to maintain manufacturing ecosystems on both sides of the world, those cost advantages could begin to erode.
Kallianpur warns of exactly this possibility. “The important distinction, however, is where the investment occurs,” he says.
If Indian companies merely expand formulation manufacturing in the US while continuing to import active pharmaceutical ingredients, intermediates and key starting materials from elsewhere, “that would not be building supply-chain resilience.”
The deeper challenge for India, therefore, is not simply to prevent factories from moving abroad. It is to move further up the pharmaceutical value chain.
Kallianpur argues that the real prize lies in expanding India’s capabilities in active pharmaceutical ingredients (APIs), intermediates, complex chemistry, biologics, contract development and manufacturing services, and advanced manufacturing.
That is particularly important because a geographically diversified supply chain is not necessarily a resilient one. A tablet may be manufactured in the US, but if its critical ingredients originate from a highly concentrated overseas supply base, strategic dependence has merely changed its location.
The Sun Pharma deal, therefore, raises a bigger question for India: should it view US localisation as the loss of Indian manufacturing – or as an opportunity to retain higher-value stages of the pharmaceutical supply chain at home while companies expand globally?
Despite the recent decline in exports, the US remains far too important for Indian drugmakers to ignore.
India’s pharmaceutical exports to the US stood at $9.47 billion in FY26, down nearly 10% from the previous year, according to Pharmexcil data. The decline reflected a combination of a high base, generic price erosion, inventory correction and product-cycle factors rather than a fundamental collapse in demand.
Indeed, Namit Joshi has described the slowdown as “not a structural concern”, pointing to the continued strength of the US market and opportunities in specialty generics and injectables.
The longer-term trend also tells a more reassuring story.
India’s overall pharmaceutical exports reached about $30.5 billion in FY25, up 9.4% from the previous year and representing a dramatic expansion from just $1.9 billion in 2000-01.
The US has been central to that growth even though the story is now shifting rapidly, even though Indian companies have played a substantial role in keeping American medicines affordable.
Industry estimates cited in an IQVIA assessment have found that Indian-made medicines generated hundreds of billions of dollars in savings for the US healthcare system over the past decade, while Indian companies have become particularly important suppliers across several high-volume generic therapy areas.
That dependence creates leverage for Indian manufacturers – but it also creates exposure.
The Sun Pharma agreement could encourage other Indian drugmakers to negotiate their own arrangements with Washington. But Kallianpur’s warning is worth remembering: a template is not the same as a blueprint.
Not every company can afford US localisation. Not every portfolio has the margins to absorb it. And not every manufacturer has the same strategic dependence on the US.
“The companies that can make that additional cost economically productive through higher-value products, better pricing power and greater regulatory and political credibility will come out stronger,” Kallianpur says.
That could accelerate a wider transformation already underway in Indian pharma – from commoditised, price-sensitive generics towards speciality medicines, complex formulations, biologics and other differentiated products.
For India, the most important outcome may ultimately depend on what happens at home.
If US manufacturing commitments simply pull higher-value pharmaceutical capacity out of India, the country’s traditional cost advantage could gradually weaken. But if Indian companies use their growing global footprints to build more sophisticated research, API, biologics and advanced manufacturing ecosystems within India, the shift could strengthen the industry.
Sun Pharma’s deal, then, is bigger than one company’s tariff relief.
It may be an early signal that the next phase of the India-US pharmaceutical relationship will be shaped less by simple exports and more by strategic bargaining, local manufacturing and supply-chain security.